spironolactone has been researched along with Injury, Myocardial Reperfusion in 10 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The chronic nandrolone treatment impairs the exercise-induced cardioprotection against ischaemia/reperfusion injury by activating the cardiac renin-angiotensin-aldosterone system and downregulating KATP channel expression." | 3.80 | AT1 and aldosterone receptors blockade prevents the chronic effect of nandrolone on the exercise-induced cardioprotection in perfused rat heart subjected to ischemia and reperfusion. ( Campos de Carvalho, AC; Ferraz, EB; Marques-Neto, SR; Nascimento, JH; Njaine, B; Rodrigues, DC; Rondinelli, E, 2014) |
| "Eplerenone pretreatment reduced the arterial pressure, cardiac inotropy, and lusitropy." | 1.48 | Eplerenone pretreatment protects the myocardium against ischaemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway in diabetic rats. ( Agrawal, YO; Chandrayan, G; Goyal, SN; Mahajan, UB; Ojha, S; Patil, CR; Patil, PD, 2018) |
| "We evaluated the effects of RU28318 (RU), a selective mineralocorticoid receptor (MR) antagonist, Captopril (Capt), an angiotensin converting enzyme inhibitor, and Losartan (Los), an angiotensin receptor blocker, alone or in combination with ischemia/reperfusion- (I/R-) induced cardiac dysfunction in hearts obtained from normal and diabetic rats." | 1.39 | RU28318, an aldosterone antagonist, in combination with an ACE inhibitor and angiotensin receptor blocker attenuates cardiac dysfunction in diabetes. ( Akhtar, S; Al-Rashdan, I; Babiker, F; Benter, IF; Yousif, M, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dragasevic, N | 1 |
| Savic, M | 1 |
| Mihajlovic, K | 1 |
| Zivkovic, V | 1 |
| Andjic, M | 1 |
| Draginic, N | 1 |
| Zdravkovic, N | 1 |
| Bolevich, S | 2 |
| Jakovljevic, V | 1 |
| Nikolic Turnic, T | 1 |
| Mahajan, UB | 1 |
| Patil, PD | 1 |
| Chandrayan, G | 1 |
| Patil, CR | 1 |
| Agrawal, YO | 1 |
| Ojha, S | 1 |
| Goyal, SN | 1 |
| Bulluck, H | 2 |
| Fröhlich, GM | 2 |
| Nicholas, JM | 1 |
| Mohdnazri, S | 2 |
| Gamma, R | 1 |
| Davies, J | 1 |
| Sirker, A | 2 |
| Mathur, A | 2 |
| Blackman, D | 1 |
| Garg, P | 1 |
| Moon, JC | 2 |
| Greenwood, JP | 2 |
| Hausenloy, DJ | 2 |
| Benter, IF | 1 |
| Babiker, F | 1 |
| Al-Rashdan, I | 1 |
| Yousif, M | 1 |
| Akhtar, S | 1 |
| Marques-Neto, SR | 1 |
| Ferraz, EB | 1 |
| Rodrigues, DC | 1 |
| Njaine, B | 1 |
| Rondinelli, E | 1 |
| Campos de Carvalho, AC | 1 |
| Nascimento, JH | 1 |
| Yoshino, T | 1 |
| Nagoshi, T | 1 |
| Anzawa, R | 1 |
| Kashiwagi, Y | 1 |
| Ito, K | 1 |
| Katoh, D | 1 |
| Fujisaki, M | 1 |
| Kayama, Y | 1 |
| Date, T | 1 |
| Hongo, K | 1 |
| Yoshimura, M | 1 |
| Gamma, RA | 1 |
| Davies, JR | 1 |
| Clesham, GJ | 1 |
| Sayer, JW | 1 |
| Aggarwal, RK | 1 |
| Tang, KH | 1 |
| Kelly, PA | 1 |
| Jagathesan, R | 1 |
| Kabir, A | 1 |
| Robinson, NM | 1 |
| Blackman, DJ | 1 |
| Ariti, C | 1 |
| Krishnamurthy, A | 1 |
| White, SK | 1 |
| Meier, P | 1 |
| Ashton, AW | 1 |
| Le, TY | 1 |
| Gomez-Sanchez, CE | 1 |
| Morel-Kopp, MC | 1 |
| McWhinney, B | 1 |
| Hudson, A | 1 |
| Mihailidou, AS | 2 |
| Loan Le, TY | 1 |
| Mardini, M | 1 |
| Funder, JW | 1 |
| Schmidt, K | 1 |
| Tissier, R | 1 |
| Ghaleh, B | 1 |
| Drogies, T | 1 |
| Felix, SB | 1 |
| Krieg, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| MINeralocorticoid Receptor Antagonist Pretreatment to MINIMISE Reperfusion Injury After ST-Elevation Myocardial Infarction (STEMI)[NCT01882179] | Phase 3 | 61 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for spironolactone and Injury, Myocardial Reperfusion
| Article | Year |
|---|---|
Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial.
Topics: Aged; Canrenoic Acid; Cardiac Imaging Techniques; Double-Blind Method; Female; Humans; Magnetic Reso | 2019 |
Mineralocorticoid receptor antagonist pretreatment to MINIMISE reperfusion injury after ST-elevation myocardial infarction (the MINIMISE STEMI Trial): rationale and study design.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Electrocardiography; Humans; Magnet | 2015 |
8 other studies available for spironolactone and Injury, Myocardial Reperfusion
| Article | Year |
|---|---|
The impact of different diuretics on regression of myocardial reperfusion injury in spontaneously hypertensive rats.
Topics: Animals; Diuretics; Hydrochlorothiazide; Indapamide; Ischemia; Male; Myocardial Reperfusion; Myocard | 2023 |
Eplerenone pretreatment protects the myocardium against ischaemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway in diabetic rats.
Topics: Animals; Cardiotonic Agents; Diabetes Mellitus, Experimental; Eplerenone; Male; Myocardial Reperfusi | 2018 |
RU28318, an aldosterone antagonist, in combination with an ACE inhibitor and angiotensin receptor blocker attenuates cardiac dysfunction in diabetes.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Diab | 2013 |
AT1 and aldosterone receptors blockade prevents the chronic effect of nandrolone on the exercise-induced cardioprotection in perfused rat heart subjected to ischemia and reperfusion.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cardiomegaly; Heart; KATP Channels; Losartan; Male | 2014 |
Preconditioning actions of aldosterone through p38 signaling modulation in isolated rat hearts.
Topics: Aldosterone; Animals; Eplerenone; Heart; Ischemic Preconditioning, Myocardial; Male; Myocardial Repe | 2014 |
Role of Nongenomic Signaling Pathways Activated by Aldosterone During Cardiac Reperfusion Injury.
Topics: Aldosterone; Amines; Animals; Calmodulin-Binding Proteins; Male; Membrane Proteins; Mineralocorticoi | 2015 |
Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction.
Topics: Aldosterone; Angina, Unstable; Animals; Apoptosis; Dexamethasone; Glucocorticoids; Hormone Antagonis | 2009 |
Cardioprotective effects of mineralocorticoid receptor antagonists at reperfusion.
Topics: Animals; Canrenoic Acid; Eplerenone; Ischemic Preconditioning, Myocardial; Mice; Mice, Knockout; Min | 2010 |